It is currently unknown whether SLCO1B1 could have utility for predicting lovastatin-induced myopathy because, to our knowledge, SLCO1B1 variation has not been studied for an association with lovastatin-induced myopathy or pharmacokinetics. This evidence concerns the gene SLCO1B1 and myopathy.